The EPS miss and lack of revenue/guidance updates are negative signals; traders should monitor the AAN presentations for clinical data that could support future commercial potential of azetukalner, but near-term sentiment may remain pressured.
Price Chart
Executive Summary
Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of -$1.20, a 9.4% negative surprise. The company highlighted upcoming Phase 3 X-TOLE2 data presentations at AAN 2026, including long-term efficacy and safety data for azetukalner in focal onset seizures, but provided no revenue or guidance updates.
Key Financial Metrics
Key Facts
- Reported Q4 2025 EPS of -$1.31, missing consensus of -$1.20 by 9.4%
- Reported revenue of $1.0M, in line with consensus
- No revenue or earnings guidance was provided
- Announced five abstracts at AAN 2026, including a Late-breaking Science oral presentation of Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures
- Presented long-term 48-month data from X-TOLE open-label extension and real-world burden of titration in epilepsy
Financial Impact
EPS miss of 9.4% below expectations, no revenue growth or guidance provided
Risk Factors
- Clinical data from X-TOLE2 may not meet efficacy or safety expectations
- Delayed or failed regulatory approval for azetukalner
- Dilution risk from future capital raises given negative EPS and limited revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269108 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 16w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access